- Home
- EXAS
as 12-18-2024 10:36am EST
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 11.6B | IPO Year: | N/A |
| Target Price: | $72.80 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $40.62 - $79.62 | Next Earning Date: | 11-05-2024 |
| Revenue: | $2,692,328,000 | Revenue Growth: | 11.91% |
| Revenue Growth (this year): | 11.81% | Revenue Growth (next year): | 11.41% |
Stock Insider Trading Activity of Exact Sciences Corporation (EXAS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Conroy Kevin T | EXAS | President and CEO | Nov 13 '24 | Buy | $51.35 | 19,500 | $1,001,325.00 | 1,074,191 | |
| Baranick Brian | EXAS | EVP, GM, Precision Oncology | Oct 8 '24 | Sell | $70.00 | 929 | $65,030.00 | 12,758 |
Latest Exact Sciences Corporation News
EXAS Breaking Stock News: Dive into EXAS Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?
Zacks
12 days ago
Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?
Simply Wall St.
13 days ago
Exploring High Growth Tech Stocks in December 2024
Morningstar Research
22 days ago
Analyst Report: Exact Sciences Corporation
Benzinga
22 days ago
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)
MT Newswires
22 days ago
BTIG Raises Price Target on Exact Sciences to $75 From $65, Maintains Buy Rating
Business Wire
22 days ago
Exact Sciences to Participate in December Investor Conferences
Business Wire
23 days ago
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
Compare EXAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXAS Exact Sciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.